17p13.3 microduplication syndrome

17p13.3 microduplication syndrome (also known as Miller-Dieker region microduplication syndrome or chromosome 17p13.3 duplication syndrome) is a rare chromosomal disorder caused by a small duplication of genetic material on the short arm of chromosome 17 at band p13.3. This region includes genes such as YWHAE and PAFAH1B1 (also known as LIS1), which play important roles in brain development. The clinical presentation varies depending on the size and exact location of the duplication, but the syndrome primarily affects the central nervous system and can also impact craniofacial development and overall growth. Key clinical features commonly reported include mild to moderate intellectual disability, developmental delay (particularly speech and motor delays), autism spectrum features, behavioral difficulties, and variable facial dysmorphisms such as a broad forehead, frontal bossing, and mild midface hypoplasia. Some individuals may also present with hypotonia, seizures, and hand or foot anomalies. Growth parameters can be variable, with some patients showing failure to thrive or short stature, while others may have normal growth. The severity of symptoms can range widely, even among individuals with similar duplication sizes, making clinical prediction challenging. There is currently no cure or specific targeted therapy for 17p13.3 microduplication syndrome. Management is supportive and symptom-based, typically involving early intervention programs, speech and occupational therapy, physical therapy, behavioral support, and special education services. Seizures, when present, are managed with standard antiepileptic medications. Regular developmental assessments and multidisciplinary follow-up with neurology, genetics, and developmental pediatrics are recommended to optimize outcomes. Genetic counseling is important for affected families to understand recurrence risks and the variable expressivity of this condition.

Common questions about 17p13.3 microduplication syndrome